DOI: 10.36347/sjmcr.2022.v10i06.019

Pages: 570-573

Ischemic heart failure is a major public health problem because of its frequency and its consequences in terms of morbidity and mortality. The incidence and prevalence of ischemic heart failure are increasing because of the aging of the population, but also because of better management of ischemic heart disease. The management of ischemic heart failure has become easier with diagnostic advances and the advent of new cardiac imaging techniques as well as therapeutic advances (inhibition of neurohormonal activation and ventricular remodeling, myocardial revascularization). In our study, we have essentially tried to highlight the different risk factors of ischemic heart failure but also some of its clinical, paraclinical, and therapeutic aspects. The treatment of ischemic heart failure in our context is in accordance with the literature, highlighting the interest of primary prevention consisting of the management of cardiovascular risk factors and the optimization of the drug treatment of these patients.